| [1] |
Bedke J, Albiges L, Capitanio U, et al. 2021 updated European association of urology guidelines on the use of adjuvant pembrolizumab for renal cell carcinoma[J]. Eur Urol, 2022, 81(2): 134-137.
|
| [2] |
Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality[J]. Nat Rev Nephrol, 2021, 17(4): 245-261.
|
| [3] |
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update[J]. Eur Urol, 2022, 82(4): 399-410.
|
| [4] |
Lindenberg L, Mena E, Choyke PL, et al. PET imaging in renal cancer[J]. Curr Opin Oncol, 2019, 31(3): 216-221.
|
| [5] |
Raveenthiran S, Esler R, Yaxley J, et al. The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma[J]. Eur J Nucl Med Mol Imaging, 2019, 46(11): 2280-2288.
|
| [6] |
Wüstemann T, Haberkorn U, Babich J, et al. Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy[J]. Med Res Rev, 2019, 39(1): 40-69.
|
| [7] |
周文瑶, 张俊. 前列腺癌PSMA PET显像剂研究进展[J]. 中华核医学与分子影像杂志, 2020, 40(12): 755-760.
|
| [8] |
Pozzessere C, Bassanelli M, Ceribelli A, et al. Renal cell carcinoma: the oncologist asks, can PSMA PET/CT answer?[J]. Curr Urol Rep, 2019, 20(11): 68.
|
| [9] |
Spatz S, Tolkach Y, Jung K, et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role[J]. J Urol, 2018, 199(2): 370-377.
|
| [10] |
Al-Ahmadie HA, Olgac S, Gregor PD, et al. Expression of prostate-specific membrane antigen in renal cortical tumors[J]. Mod Pathol, 2008, 21(6): 727-732.
|
| [11] |
Baccala A, Sercia L, Li J, et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms[J]. Urology, 2007, 70(2): 385-390.
|
| [12] |
Sawicki L M, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience[J]. Eur J Nucl Med Mol Imaging, 2017, 44(1): 102-107.
|
| [13] |
Li Y, Zheng R, Zhang Y, et al. Special issue "The advance of solid tumor research in China" ：68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma[J]. Int J Cancer, 2023, 152(1): 42-50.
|
| [14] |
Tariq A, Kwok M, Pearce A, et al. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: a multi-institutional case series with intra-individual comparison[J]. Urol Oncol, 2022, 40(2): 66.e1-66.66.e9.
|
| [15] |
邹思娟, 管维, 宋双, 等. 68Ga-PSMA与18F-FDG PET/CT探测肾透明细胞癌的比较研究[J]. 中国临床医学影像杂志, 2021, 32(12): 884-888.
|
| [16] |
张浩然, 张兴明, 朱旭东, 等. 不同部位转移灶对肾癌患者预后的影响及其对IMDC评分的改良价值[J]. 中华泌尿外科杂志, 2020, 41(6): 439-445.
|
| [17] |
Meyer AR, Carducci MA, Denmeade SR, et al. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT[J]. Ann Nucl Med, 2019, 33(8): 617-623.
|
| [18] |
Rhee H, Blazak J, Tham CM, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour[J]. EJNMMI Res, 2016, 6(1): 76.
|
| [19] |
Sadeq A, Usmani S, Esmail AA, et al. Incremental value of 18F-PSMA-1007 PET/CT in detection of metastatic renal cell carcinoma to the brain[J]. Clin Nucl Med, 2022, 47(7): 627-628.
|
| [20] |
Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT[J]. Ann Nucl Med, 2015, 29(10): 877-882.
|
| [21] |
Gorin MA, Rowe SP, Hooper JE, et al. PSMA-targeted 18F-DCFPyL PET/CT imaging of clear cell renal cell carcinoma: results from a rapid autopsy[J]. Eur Urol, 2017, 71(1): 145-146.
|
| [22] |
王观筠, 刘亚超, 关志伟, 等. PSMA-靶向18F-DCFPyL PET/CT在肾透明细胞癌术后复发或转移病灶诊断中的作用分析[J]. 解放军医学院学报, 2020, 41(12): 1176-1180.
|
| [23] |
熊斌, 鲁伟. 转移性肾癌治疗的现状和进展[J]. 中华泌尿外科杂志, 2021, 42(4): 308-311.
|
| [24] |
Mittlmeier LM, Unterrainer M, Rodler S, et al. 18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results[J]. Eur J Nucl Med Mol Imaging, 2021, 48(6): 2031-2037.
|
| [25] |
Mittlmeier LM, Unterrainer M, Todica A, et al. PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma[J]. Eur J Nucl Med Mol Imaging, 2020, 47(9): 2216-2217.
|
| [26] |
Meng L, Zhang S, Gao J, et al. 68Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2α expression and therapeutic response to HIF-2α antagonists in patients with RCC[J]. Eur Radiol, 2022, 32(9): 6545-6553.
|
| [27] |
Gao J, Meng L, Xu Q, et al. 68Ga-PSMA-11 PET/CT parameter correlates with pathological VEGFR-2/PDGFR-β expression in renal cell carcinoma patients[J]. Mol Imaging Biol, 2022, 24(5): 759-768.
|
| [28] |
Seront E, Lhommel R, Tombal B. Case report: early 68Ga-PSMA-PET metabolic assessment and response to systemic treatment for first-line metastatic clear cell renal cell carcinoma; about two clinical cases[J]. Front Oncol, 2021, 11: 782166.
|
| [29] |
Gao J, Xu Q, Fu Y, et al. Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma[J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 561-569.
|
| [30] |
Terakawa T, Miyake H, Kusuda Y, et al. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib[J]. Urol Oncol, 2013, 31(4): 493-498.
|
| [31] |
Lee JN, Chun SY, Ha YS, et al. Target molecule expression profiles in metastatic renal cell carcinoma: development of individual targeted therapy[J]. Tissue Eng Regen Med, 2016, 13(4): 416-427.
|
| [32] |
Jiang W, Wang D, Liu X, et al. PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy[J]. Urol Oncol, 2021, 39(1): 78.e9-78.78.e16.
|
| [33] |
Xiong Z, Xiong W, Xiao W, et al. NNT-induced tumor cell "slimming" reverses the pro-carcinogenesis effect of HIF2a in tumors[J]. Clin Transl Med, 2021, 11(1): e264.
|
| [34] |
Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, et al. Targeting HIF-2α in clear cell renal cell carcinoma: a promising therapeutic strategy[J]. Crit Rev Oncol, 2017, 111: 117-123.
|